Norton L et al. Nature Med 2006
|
|
- Joleen French
- 5 years ago
- Views:
Transcription
1 New Bone Targeting Agents Ana Maria Gonzalez-Angulo, M.D. Associate Professor Section Chief, Clinical Research and Drug Development Breast Medical Oncology Systems Biology Padua, Italy 11/2012
2 Outline Bone physiology and bone metastatsis t t The bisphosphonate story Denosumab New agents: Everolimus Cabozantinib Dasatinib Ra-223 Anti-sclerostin mab
3 Self-Seeding Seeding Theory of Metastasis In breast cancer bone is typically the First site of metastases Most common site of metastases Norton L et al. Nature Med 2006
4 What Might Bisphosphonates Do? Directly alter tumor cell behavior Alter the micro-environment by inducing changes Vasculature Immune modulating cells Bone cells/bone matrix Hematopoietic cells
5 Vicious Cycle PTHrP IL-6 IL-8 PGE 2 TNF- CSF-1 BMP PDGF FGFs IGFs TGFβ Roodman et al. N Engl J Med 2004
6 Breaking the Vicious Cycle X Anti-cancer therapy X Adjunctive Bone directed therapy Modified from Roodman. N Engl J Med 2004
7 Bone Metastases & SREs Skeletal Related Events (SREs) Fracture Need for radiation to bone Need for surgery to bone Spinal cord compression Hypercalcemia of malignancy Oncologic Emergency
8 Bone Modifying Agents in Clinical Practice Pivotal Trials in MBC: Endpoint SREs Hortobagyi NEJM 1996 Pamidronate vs Placebo (both + Chemo) Theriault JCO 1999 Pamidronate vs Placebo (both + Endocrine) Rosen Cancer J 2001 Pamidronate vs. Zoledronic acid Kohno JCO 2005 Zoledronic acid vs Placebo Stopeck JCO 2010 Denosumab vs Zoledronic Acid ASCO: Update on the Role of Bone Modifying Agents in Metastatic Breast Cancer Van Poznak, J Clin Oncol 2011
9 Neo-Adjuvant Zoledronic Acid & Disseminated Tumor Cells Baseline At surgery Zoledronic Acid Treated Control Aft et al. Lancet Onc 2010 Solomayer et al. Ann Onc 2012
10 Adjuvant Bisphosphonate p Clinical Trials: Primary Endpoints Bone metastases free survival Diel NEJM 1998: clodronate (+) Sarto JCO 2001: clodronate (-) Powles JCO 2002: clodronate (+) Disease free survival Gnant NEJM 2009: Coleman NEJM 2011: Mobus SABCS 2011: zoledronic acid (+) zoledronic acid (-) ibandronate (-) Paterson Lancet Oncol 2012: clodronate (-) Ongoing adjuvant studies are investigating Bisphosphonates Denosumab
11 ABCSG-12: Disease Free Survival Primary Endpoint Gnant et al. N Engl J Med 2009
12 ABCSG-12: DFS and OS by Age Gnant et al. SABCS 2011
13 Adjuvant Bisphosphonate p Seven studies & 3 bisphosphonates AZURE, ABCSG-12, Z/E-Zo/Z0-FAST, NSABP B-34 34, GAIN Postmenopausal Meta-Analysis Authors acknowledge approximations made due to limited details available Gregory et al. ASCO 2012 Abstract #513
14 BISMARK: Dosing of IV Bisphosphonate by Markers of Bone Turnover Met Breast Cancer to bone R A N D O M I Z E Zoledronic Acid Every 4 weeks Zoledronic Acid Dosed by Markers of Bone Resorption Follow For SREs Planned N= 1500 Study closed early due to poor accrual with N <300 Coleman et al. ASCO 2012
15 BISMARK: untx Directed Therapy Time to First SRE Larger number of SREs in M-Zol 150 vs 109 in S-Zol More patients on M-Zol experienced multiple SREs NTX levels were higher in M-Zol group at all time points Coleman et al. ASCO 2012
16 Study of Dosing Intervals in Prolonged Zoledronic Acid Use: ZOOM Metastatic Breast Cancer to bone 9-12 prior doses of zoledronic acid R A N D O M I Z E Zoledronic Acid Every 4 weeks Zoledronic Acid Every 12 weeks No Statistical tistic Difference in Skeletal Morbidity Rate OPEN LABEL Approx 300 patients Variable Intervals for: Clinical Assessments Imaging Assessments CALGB NCT Optimize-2 NCT Ripamonti et al. ASCO 2012
17 Balancing Bone Mass Osteoclast Bone Resorption Osteoblast Bone Formation RANKL Osteoprotegerin (OPG) Courtesy of Van Poznak 2012
18 Modulation of Osteoclast Differentiation RANKL is important to osteoclast differentiation Suda et al. Endocrine Rev 2003
19 Phase III Denosumab vs Zoledronic Acid Time to 1 st SRE ( 18%) Time to 1 st & Subsequent SREs ( 23%) Overall Survival: No Change Time to Progression: No Change Renal Toxicity: 4.9% (Dmab Dmab) vs 8.5% (ZA) ONJ: 2.0% (Dmab Dmab) vs 1.4% (ZA) Denosumab mean skeletal morbidity rate by 22% compared with ZA (0.45 vs events respectively) Stopeck et al. J Clin Oncol 2010
20 Uniformity Across 3 Parallel Phase III Studies Time to First SRE: Denosumab vs. Zoledronic acid Courtesy of Van Poznak 2012
21 Uniformity Across 3 Parallel Phase III Studies Time to First & Subsequent SREs: Denosumab vs. Zoledronic acid Courtesy of Van Poznak 2012
22 Skeletal Complication Risk: Incremental nt Benefits in Breast Cancer No bisphosphonate 64% 2 yrs Pamidronate ~ 20% risk reduction Zoledronic acid ~ 20% risk reduction Denosumab 18% risk reduction 64% 51% 34% 27% Lipton et al. Cancer 2000 Rosen et al. Cancer J 2003 Stopeck et al. J Clin Oncol 2010
23 Bone Modifying Agents (Osteoclast Inhibitors) in MBD Approved throughout the world for reduction in SREs in patients with Metastatic Bone Disease Denosumab Pamidronate (IV) Zoledronic acid (IV) Clodronate (IV, oral) Ibandronate (IV, oral) Approved in USA & outside of USA for MBD Approved for MBD Outside USA Osteoclast inhibition the risk of SREs ~ 30% Denosumab > zoledronic acid for SRE Zoledronic acid > pamidronate for Hypercalcemia of Malignancy Stopeck et al. J Clin Oncol 2010 and Major et al. J Clin Oncol 2001
24 Uncommon Adverse Events Associated with ih Bisphosphonates: h Etiology Eil Unknown Uk Atypical Fractures Osteonecrosis of the Jaw (ONJ) ONJ has also been seen with Denosumab
25 Bone Metastases Systemic Treatment Considerations Osteoclast inhibitors Other targets Bisphosphonates CXCR4 antagonists Denosumab Anti-CCR2 antibodies Gallium nitrate HDAC inhibitors Calcitonin Α v β 3 integrin inhibitors Src inhibitors TGF-β inhibitors cmet inhibitors Established practice of IVBP: Endothelin A antagonists t When to initiate therapy? mtor inhibitors Optimal dose? SOST/SclerostinSclerostin Optimal schedule? PDGFR inhibitors Duration of therapy? and more.
26 Role of SRC Inhibition in Bone Metastases During bone metastasis, systemic factors in the bone environment and bone-derived growth factors activate the release of stimulants of osteoclast activity SRC signaling has a central role in tumor cell and osteoclast function Dasatinib inhibitory SRC activity has a potential role in the prevention/treatment of osteolytic metastases Araujo et al. Cancer Treat Rev 2010
27 Phase II : Randomized Between Dasatinib Dosing MBC to bone R A N D O M I Z E Dasatinib ib 70mg Twice Daily Follow For PFS & Dasatinib correlatives 100mg Daily No concurrent bisphosphate use Accrual met, analysis ongoing
28 TBCRC 010: Dasatinib & Zolendronate in MBC with Predominant Bone disease
29 Role of PI3K Signaling in Osteoclast Survival PI3K inh MEK inh Rapalogs Adapted from Glantschnig et al. Cell Death Differ 2003
30 mtor Inhibition Decreases Bone Resorption and Osteoclast Maturation and Increases Osteoclast Apoptosis in Mice Adapted from Glantschnig et al. Cell Death Differ 2003
31 BOLERO-2 Study: Exemestane ± Everolimus in Patients with ABC Progressing After NSAIs N = 724 PMW with HR+ HER2- ABC refractory to LET or ANA, defined as Recurrence during or within 12 months after end of adjuvant treatment, or Progression during or within 1 month after end of treatment for advanced disease EVE 10 mg/day + EXE 25 mg/day (n = 485) Placebo + EXE 25 mg/day h h (n = 239) Primary endpoint: PFS Secondary endpoints: OS, ORR, CBR, safety, QoL, bone markers Stratification Sensitivity to prior hormonal therapy Presence of visceral disease No crossover Baselga et al. N Engl J Med. 2012
32 eline, % from Base Change f BOLERO-2: Bone Markers BSAP (18 18-Month Follow-Up Up) 6 weeks 12 weeks Bone Formation 20.9 P1NP Bone Resorption CTX 29.5 Bone Formation BSAP 18.1 Bone Resorption P1NP CTX % 56% 36% 20% 66% 40% EVE + EXE PBO + EXE -40 Gnant M,et al. ASCO 2012
33 BOLERO-2: Disease Progression in Bone (18-Month Follow-Up) 0.5 Overall Population 0.5 Patients with Bone Metastases at Baseline se es e of Diseas e Metastase e Incidence n from Bone Cumulative Progression EVE + EXE (n = 485) 0.4 PBO + EXE (n = 239) P =.0363 (Gray s test) e es of Disease e Metastase e Incidence n from Bone Cumulative Progression EVE + EXE (n = 371) PBO + EXE (n = 185) P =.0165 (Gray s test) Time, weeks Time, weeks Gnant M,et al. ASCO 2012
34 Everolimus Therapy Decreases Bone Loss Associated with Estrogen Deprivation in Models Kneissel et al. Bone 2004
35 Role for MET and VGEF Inhibition in Bone Metastases MET is highly expressed in bone metastases t OB & OC express MET & VEGFR2 and respond to the ligands of HGF & VEGF HGF & VEGF appear to direct cross-talk between tumor cells, OB & OC Courtesy of Schimmoller 2011
36 Phase II Study of Cabozantinib (XL184) in Metastatic Prostate Cancer All patients had a PR and pain control Hussain et al. ASCO 2011
37 Phase I Cabozantinib (XL-184) Breast Cohort Objective tumor shrinkage in heavily pre- treated patients 2/3 of patients with bone metastasis experieced partial resolution by bone scan Symptomatic pain relief associated with bone scan improvement Phase II in ER+ breast cancer with dominant bone disease Gordon et al. ASCO 2011
38 Radium-223 Alpharadin Radiopharmaceutical Acts as a Calcium mimetic Alpha particles induced DNA double strain breaks in tumor cells Bowel clearance Phase III in prostate cancer (+) overall survival advantage reported but not published Phase II in breast cancer NCT accrued not reported
39 Anti-CCR2 Antibody MLN1202 SWOG 0916 Cifuentes et al. Clin Chimica Acta
40 Anti-Sclerostin mab and TKI Sclerostin has an inhibitory effect on bone formation It prevents the activation of lining cells as well as the inactivation of active osteoblasts Anti-sclerostin antibody for osteoporosis is in Phase III Small molecule l inhibitors hb in development Sclerostin has anabolic effects and is not favored for trials in breast cancer at this time Kamilla et al. Development 2008
41 Conclusions Bisphosphanates still the SOC for patients with bone metastasis Denusumab is an excellent option for the same patient population and preferred for patients with renal disfunction Multiple drugs being developed to target the fisiology of bone disease Exciting data with mtor inhibition and cmet/vegf inhibition Need to do a better work on techniques to measure disease and biomarker development for patient selection and follow up of disease
42 Thank you!!!! Cathy Van Poznak, MD Gabriel N. Hortobagyi, MD Michael Gnant, MD org
Managing Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationManaging Skeletal Metastases
Managing Skeletal Metastases Alison Stopeck, M.D. Professor of Medicine Director, Breast Cancer Program University of Arizona Cancer Center Tucson, AZ Disclosures: Consulting, research funding, and honoraria
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationQuando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata
Quando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata Igor A. Protzner Morbeck, MD, MSc Professor de Medicina Universidade Católica de Brasília Oncologista Clínico Onco-Vida Brasília-DF
More informationFarmaci bone-targeted: basi biologiche e razionale d uso. Giovanni Pavanato Rovigo
Farmaci bone-targeted: basi biologiche e razionale d uso Giovanni Pavanato Rovigo DICHIARAZIONE Relatore: Giovanni Pavanato Come da nuova regolamentazione della Commissione Nazionale per la Formazione
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationBone Health in the Cancer Patient. Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Overview Healthy bone is in a constant state of remodelling
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationBone Health in the Cancer Patient
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Sacred Encounters Perfect Care Healthiest Communities Why
More informationWinston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida
Winston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida } none } To develop an understanding of the management of bone metastasis through a multidisciplinary approach } Enable the learner
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationManagement of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration
Management of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration Kara Laing, MD, FRCPC Chair and Associate Professor, Discipline of Oncology Memorial University of Newfoundland Medical Oncologist,
More informationNew Developments in Oncology Bone Health. Learning Objectives. Disclosures 10/1/2014
New Developments in Oncology Bone Health Kamakshi V. Rao, Pharm.D., BCPOP, CPP, FASHP Clinical Manager, Pharmacy Residency Programs Oncology and Bone Marrow Transplant Clinical Pharmacist University of
More informationThe management and treatment options for secondary bone disease. Omi Parikh July 2013
The management and treatment options for secondary bone disease Omi Parikh July 2013 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan,
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationBone metastases in hematology
Botziekte bij hematologische tumoren Prof. Dr. Michel Delforge Hematologie, UZ Leuven Bone metastases in hematology The bone marrow is the source of many hematological malignancies However, bone damage
More informationTreating and Preventing Bone Metastases 10 th International Future of Breast Cancer Congress Coronado, CA 6 Aug 2011
Frankie Ann Holmes, MD, FACP Houston, TX Treating and Preventing Bone Metastases 10 th International Future of Breast Cancer Congress Coronado, CA 6 Aug 2011 Treating and Preventing Bone Mets What is the
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More information8/8/2011. Treating and Preventing Bone Metastases 10 th International Future of Breast Cancer Congress Coronado, CA 6 Aug 2011
Frankie Ann Holmes, MD, FACP Houston, TX Treating and Preventing Bone Metastases 10 th International Future of Breast Cancer Congress Coronado, CA 6 Aug 2011 Treating and Preventing Bone Mets What is the
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationPage 1. Breast Cancer 101: Update on Treatment. Breast Cancer: Prognostic and Predictive Factors
Breast Cancer 101: Update on Treatment Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer University of Washington School of Medicine Fred Hutchinson
More informationNew Agents for Myeloma Bone Disease
New Agents for Myeloma Bone Disease G. David Roodman MD PhD University of Pittsburgh Bone Remodeling is Uncoupled in Myeloma Normal Myeloma Hattner R et al. Nature. 1965;206:489. 1 Myeloma Bone Disease
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationBisphosphonates in Breast Cancer: Antitumor Effects
Bisphosphonates in Breast Cancer: Antitumor Effects Rebecca Aft, MD, PhD Dr. Aft is a Professor of Surgery in the Division of General Surgery at the Washington University School of Medicine in St. Louis,
More informationNovel therapies for Myeloma bone disease. Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah
Novel therapies for Myeloma bone disease Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah 1 Introduction Multiple myeloma (MM) is a plasma cell
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationAgenda. Adjuvant Bisphosphonates: Ready For Prime Time? The Osteoporosis Equation. Risk Factors for Osteoporosis. Charles L.
Adjuvant Bisphosphonates: eady For Prime Time? The Osteoporosis Equation Aging, family history, race, menopause [estrogen deficiency] diet, exercise, smoking, alcohol, meds Charles L. Shapiro, MD Director
More informationManagement of Bone Metastases
Management of Bone Metastases Mustafa Ozdogan, MD Medical Oncologist Akdeniz University Antalya/TURKEY Bone Metastases: Scope of the Problem Bone metastases affect more than 500,000 patients in the United
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationXgeva. Xgeva (denosumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.18 Subject: Xgeva Page: 1 of 5 Last Review Date: March 16, 2018 Xgeva Description Xgeva (denosumab)
More informationMultiple Myeloma Bone Disease
The 4th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA May 3-5, 2018 Paris, France Multiple Myeloma Bone Disease Evangelos Terpos MD, PhD Plasma Cell Dyscrasias Unit,, National & Kapodistrian, School
More informationBone metastases of solid tumors Diagnosis and management by
Bone metastases of solid tumors Diagnosis and management by Dr/RASHA M Abd el Motagaly oncology consultant Nasser institute adult oncology unit 3/27/2010 1 Goals 1- Know the multitude of problem of bone
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationRadiopharmaceuticals for treating CRPC patients with metastatic bone disease 2014/6/27
Radiopharmaceuticals for treating CRPC patients with metastatic bone disease 和信醫院黃玉儀 2014/6/27 Bone metastases in prostate cancer The most common site of metastasis in prostate cancer In >90% patients
More informationIdentification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital
Advances in Breast Cancer Research, 2018, 7, 120-129 http://www.scirp.org/journal/abcr ISSN Online: 2168-1597 ISSN Print: 2168-1589 Identification of the Risk Factors of Bone Metastatic among Breast Cancer
More informationMetastatic Bone Disease in Patients with Solid Tumors Burden of Bone Disease and the Role of Zoledronic Acid
REVIEW Metastatic Bone Disease in Patients with Solid Tumors Burden of Bone Disease and the Role of Zoledronic Acid Vera Hirsh Departments of Medicine and Oncology, McGill University Health Centre, Royal
More informationA KL/R / AN A K/O / P O G G
Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationAgents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors
Agents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors Valero, M.D., Professor of Medicine and Deputy Chairman Department of Breast Medical Oncology The
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationXgeva. Xgeva (denosumab) Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.18 Subject: Xgeva Page: 1 of 5 Last Review Date: December 3, 2015 Xgeva Description Xgeva (denosumab)
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationThe Role of Bisphosphonates in Early Breast Cancer
The Role of Bisphosphonates in Early Breast Cancer Alexander H.G. Paterson Tom Baker Cancer Centre and University of Calgary, Calgary, Alberta, Canada Key Words. Bisphosphonates Bone metastases Adjuvant
More informationManagement of Acute Oncological emergencies
Management of Acute Oncological emergencies Malignant Spinal cord compression (MSCC) Neutropenic sepsis Superior vena caval obstruction Hypercalcemia Hyponatremia Bowel obstruction Brain Metastasis with
More informationMonitoring therapy and mitigating side effects
Monitoring therapy and mitigating g side effects Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Associate Professor of Medicine Harvard Medical School Issues with BP Therapy Renal
More informationOsteoporosis management in cancer patients
Osteoporosis management in cancer patients Belgian Menopause Society - Osteoporosis - Brussels, Oct 2017 Prof. JJ Body CHU Brugmann Univ. Libre de Bruxelles Brussels Bone loss associated with hormone ablation
More informationAlpha-emitting Radionuclides: Ra-223
Alpha-emitting Radionuclides: Ra-223 prof. dr. K. Goffin Nuclear Medicine and Molecular Imaging Department of Imaging & Pathology UZ Leuven KU Leuven Belgium International Course on Theranostics and Molecular
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationMetastatic HR+, TNBC, & Bisphosphonates Abstracts
GASCO 2011 San Antonio Breast Cancer Symposium Review Metastatic HR+, TNBC, & Bisphosphonates Abstracts Thomas A. Samuel, MD Associate Professor of Medicine Georgia Health Sciences University Director,
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationLes toxicités du cancer: l os. Matti S. Aapro Cancer Center Genolier Switzerland
1 Les toxicités du cancer: l os Matti S. Aapro Cancer Center Genolier Switzerland COI Dr Aapro is/was a consultant for Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, GSK, Helsinn, Hospira, JnJ,
More informationBisphosphonates and Breast Cancer
Bisphosphonates and Breast Cancer Bisphosphonates Analogues of pyrophosphate Carbon substitution makes them resistant to endogenous phosphatases in circulation Potent inhibitors of osteoclast growth, maturation
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationBone health in cancer patients: ESMO Clinical Practice Guidelines
clinical practice guidelines Annals of Oncology 25 (Supplement 3): iii124 iii137, 2014 doi:10.1093/annonc/mdu103 Published online 29 April 2014 clinical practice guidelines Bone health in cancer patients:
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationTargeting mtor pathway in ER+/Her2- breast cancers. Fabrice ANDRE Gustave Roussy
Targeting mtor pathway in ER+/Her2- breast cancers Fabrice ANDRE Gustave Roussy Outline mtor pathway Clinical development of rapalogs in breast cancer Moving beyond rapalogs mtor pathway LKB1 Ras-raf-
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationDENOSUMAB. . Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB. RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer
DENOSUMAB. Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer. Peter Harper Guy s, King s & St Thomas & Leaders in
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationBiology of Bone Metastases
Knowledge about the biologic mechanisms of bone metastasis is guiding the development of effective interventions. Ferruginous Hawk_0242. Photograph courtesy of Henry Domke, MD. www.henrydomke.com Biology
More informationBone Protection and Improved Survival
Bone Protection and Improved Survival Professor Rob Coleman Weston Park Hospital Sheffield Cancer Research Centre University of Sheffield UK Trans Atlantique en Oncologie Paris November 20 th 21 st November
More informationBone Metastases and Osteoporosis
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Bone Metastases and Osteoporosis Bone Metastases Version 2002: Dall / Fersis / Friedrich Version 2003 2009: Bischoff / Böhme
More informationEndocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationOsteooncology and Bone Health
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Osteooncology and Bone Health Osteooncology and Bone Health Versions 2002 2017: Bischoff / Böhme / Brunnert / Dall / Diel /
More informationKey words: Bisphosphonates, guidelines, drug use evaluation, breast cancer
DO PHYSICIA FOLLOW SYSTEMIC TREATMENT AND FUNDING POLICY GUIDELINES? A REVIEW OF BISPHOSPHONATE USE IN PATIENTS WITH BONE METASTASES FROM BREAST CANCER Mark Clemons 1, Katherine Enright 1, Annemarie Cesta
More informationMyeloma Bone Disease. Evangelos Terpos, MD, PhD. National & Kapodistrian University of Athens, School of Medicine, Athens, Greece
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Myeloma Bone Disease Disclosure of Conflict of Interest
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationOSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010
OSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010 Alessandria, 5 giugno 2010 Novità nel trattamento dell osteoporosi Stefania Boldini Francesco Bertoldo Dipartimento di
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationOncologist. The. Academia Pharma Intersect: Symptom Management and Supportive Care
The Oncologist Academia Pharma Intersect: Symptom Management and Supportive Care Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases MATTI AAPRO, a FRED SAAD, b LUIS
More information